IMPACT ON PARTNERS

Alza – TransForm is developing a one-of-a-kind, high throughput platform, for the rapid identification of superior transdermal formulations. The technology is being developed and operated at TransForm, and will potentially enable passive transdermal delivery of products previously not thought possible to deliver in this way.

Lilly – TransForm has been collaborating with Lilly in a number of areas, to address solubility challenges at different points in Lilly’s small molecule pipeline, from lead optimization through to early clinical development.

Roche – TransForm scientists succeeded in identifying a crystalline form of a development candidate that had previously resisted all attempts at crystallization, and have thereby enabled further development of that compound.